Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1978 Jul;33(1):71–78.

Inhibition of lymphocyte cytotoxicity in chronic active hepatitis.

S Kakumu, T Hara, H Gohji, N Sakamoto
PMCID: PMC1537516  PMID: 709913

Abstract

Inhibitory factors were investigated, using 51Cr-labelled Chang cells as targets, based on the inhibition of lymphocyte-mediated cytotoxicity (LMC) in patients with chronic active hepatitis (CAH). A significant reduction of LMC was noted (P less than 0.001) when autologous sera of patients with CAH was added. The addition of HBsAg-positive and -negative homologous sera from CAH, which were as capable of inhibiting LMC as autologous sera, decreased LMC significantly (P less than 0.001). The LMC fell significantly (P less than 0.001) in the presence of sera of patients with rheumatoid arthritis. A significantly higher inhibition (P less than 0.001) by rheumatoid factor (RF) positive autologous sera of patients with CAH was observed when compared to that of RF-negative sera. Such autologous sera inhibiting LMC contained increased IgG levels (P less than 0.01) when compared to those that failed to inhibit LMC. A significant reduction of LMC was also induced with the addition of anti-HBs (P less than 0.05), HBsAg--anti-HBs (P less than 0.001) and IgG--anti-IgG (P less than 0.01) complexes, or aggregated IgG (P less than 0.001). The LMC was reduced significantly (P less than 0.001) after adding a purified liver-specific membrane lipoprotein (LSP) from human livers. There was some evidence for the inhibition of LMC being effected by these additives as a result of their acting on an effector cell level. These findings suggest that humoral factors including immune complexes, aggregated IgG and LSP play an important role for lymphocyte cytotoxicity in the pathogenesis of CAH.

Full text

PDF
71

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cochrane A. M., Moussouros A., Thomsom A. D., Eddleston A. L., Wiiliams R. Antibody-dependent cell-mediated (K cell) cytotoxicity against isolated hepatocytes in chronic active hepatitis. Lancet. 1976 Feb 28;1(7957):441–444. doi: 10.1016/s0140-6736(76)91472-0. [DOI] [PubMed] [Google Scholar]
  2. Cowdery J. S., Jr, Treadwell P. E., Fritz R. B. A radioimmunoassay for human antigen-antibody complexes in clinical material. J Immunol. 1975 Jan;114(1 Pt 1):5–9. [PubMed] [Google Scholar]
  3. Dudley F. J., Fox R. A., Sherlock S. Cellular immunity and hepatitis-associated, Australia antigen liver disease. Lancet. 1972 Apr 1;1(7753):723–726. doi: 10.1016/s0140-6736(72)90234-6. [DOI] [PubMed] [Google Scholar]
  4. FRANKLIN E. C., HOLMAN H. R., MULLER-EBERHARD H. J., KUNKEL H. G. An unusual protein component of high molecular weight in the serum of certain patients with rheumatoid arthritis. J Exp Med. 1957 May 1;105(5):425–438. doi: 10.1084/jem.105.5.425. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hellström I., Sjögren H. O., Warner G., Hellström K. E. Blocking of cell-mediated tumor immunity by sera from patients with growing neoplasms. Int J Cancer. 1971 Mar 15;7(2):226–237. doi: 10.1002/ijc.2910070206. [DOI] [PubMed] [Google Scholar]
  6. Jewell D. P., MacLennan I. C. Circulating immune complexes in inflammatory bowel disease. Clin Exp Immunol. 1973 Jun;14(2):219–226. [PMC free article] [PubMed] [Google Scholar]
  7. Kakumu S., Hara T., Goji H., Sakamoto N. Lymphocyte cytotoxicity against Chang liver cells in chronic active hepatitis. Cell Immunol. 1978 Mar 1;36(1):46–53. doi: 10.1016/0008-8749(78)90249-6. [DOI] [PubMed] [Google Scholar]
  8. McFarlane I. G., Wojcicka B. M., Zucker G. M., Eddleston A. L., Williams R. Purification and characterization of human liver-specific membrane lipoprotein (LSP). Clin Exp Immunol. 1977 Mar;27(3):381–390. [PMC free article] [PubMed] [Google Scholar]
  9. Paronetto F., Vernace S. Immunological studies in patients with chronic active hepatitis. Cytotoxic activity of lymphocytes to autochthonous liver cells grown in tissue culture. Clin Exp Immunol. 1975 Jan;19(1):99–104. [PMC free article] [PubMed] [Google Scholar]
  10. Peter H. H., Pavie-Fischer J., Fridman W. H., Aubert C., Cesarini J. P., Roubin R., Kourilsky F. M. Cell-mediate cytotoxicity in vitro of human lymphocytes against a tissue culture melanoma cell line (igr3). J Immunol. 1975 Aug;115(2):539–548. [PubMed] [Google Scholar]
  11. Serum and synovial fluid inhibitors of antibody-mediated lymphocytotoxicity in rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum. 1976 Mar-Apr;19(2):142–149. doi: 10.1002/art.1780190203. [DOI] [PubMed] [Google Scholar]
  12. Thomson A. D., Cochrane M. A., McFarlane I. G., Eddleston A. L., Williams R. Lymphocyte cytotoxicity to isolated hepatocytes in chronic active hepatitis. Nature. 1974 Dec 20;252(5485):721–722. doi: 10.1038/252721a0. [DOI] [PubMed] [Google Scholar]
  13. Wands J. R., Perrotto J. L., Alpert E., Isselbacher K. J. Cell-mediated immunity in acute and chronic hepatitis. J Clin Invest. 1975 May;55(5):921–929. doi: 10.1172/JCI108021. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES